Goldman Sachs Names St. Louis Co-founder in List of Most Intriguing Entrepreneurs
EQ IQ- < 1 Min Read
463 Views- Visitors
In order to offer transparency into how our stories are produced and to teach our readers about the importance of media literacy online, EQ's editorial team provides a quick self-rating of the integrity of the articles and the facts presented against the following EQ IQ metrics.
- Published on October 29, 2021
- In Awards & Recognition
- Inspired by Press Release discovered on PR Newswire.
Co-founder, Andrew Barnell, of Geneoscopy has been recognized as one of the Most Intriguing Entrepreneurs of 2021. Barnell was selected by Goldman Sachs at the two-day of Builders + Innovators Summit, held in Healdsburg, California. The life science company focuses on the development of diagnostic tests for gastrointestinal health.
Goldman Sachs recognized co-founder and CEO of Geneoscopy, Andrew Barnell as one of 100 entrepreneurs. Barnell began his career with J.P. Morgan’s healthcare investment banking group, working primarily on M&A and capital markets transactions.
“Innovation doesn’t happen just anywhere; it thrives where there’s a wide range of thoughts and perspectives,” said David M. Solomon, Chairman & CEO of Goldman Sachs. “One of our great strengths is our ability to bring together people from different walks of life and to spark conversations today that will lead to breakthroughs tomorrow.”
Prior to co-founding Geneoscopy, he was an associate at Lindsay Goldberg, a middle-market private equity firm focused on partnering with family-owned businesses. Barnell holds a BA in Applied Economics and Management, with a specialization in Finance, from Cornell University and earned an MBA in Health Care Management and Entrepreneurial Management from The Wharton School.
“With an initial focus on colorectal cancer prevention, Geneoscopy’s technology is poised to transform gastrointestinal health by enabling earlier detection, more accurate diagnosis, and more effective therapeutic management,” said Vince Wong, Geneoscopy’s Chief Commercial Officer in a press release. “It is exciting to have Andrew’s vision for the company recognized, validating the significant impact it will have on shaping the future of gastrointestinal health.”